dsm-firmenich reports Q3 2023 results
31 Oct 2023
The company estimates for FY 2023, on a pro forma basis, an Adjusted EBITDA of around €1,800 million, which includes an estimated negative vitamin effect of about €500 million as well as a negative foreign exchange effect of about €90 million.